

## **Expert Masterclass on Limb Girdle Muscular Dystrophy**

Wednesday 23<sup>rd</sup> - Thursday 24<sup>th</sup> September 2020

### **Programme**

#### **Meeting Objectives**

- Deliver high quality educational and interactive meeting for providers diagnosing or managing the care of patients with the limb girdle muscular dystrophies by providing information on the latest in diagnosis, natural history, and care discussions.
- Provide a platform for health care providers to share ideas, challenges and successes in delivering optimal care to people with LGMD.
- Provide an overview of the current clinical trial landscape and the emerging implications on care

#### **Meeting Format**

- Wednesday 23<sup>rd</sup> September & Thursday 24<sup>th</sup> September

#### **Chairs**

- **Professor Jordi Diaz Manera**
- **Dr Lindsay Alfano**

**\*Please note more details will follow of how each session will be delivered\***

<b>Wednesday 23<sup>rd</sup> September</b>	
<b>Talk</b>	<b>Speaker</b>
<b>Welcome, programme overview and introduction to TREAT-NMD</b>	<b>Professor Jordi Diaz Manera</b> , Neurologist, John Walton Muscular Dystrophy Research Centre, UK  <b>Dr. Lindsay Alfano</b> , Physical Therapist, Nationwide Children's Hospital
<b>Patient perspective</b> <ul style="list-style-type: none"> <li>• Psychosocial impact</li> </ul>	<b>TBC</b>
<b>LGMD Overview, Definitions &amp; Classification</b>	<b>Dr. Matthew Wicklund</b> , Neurologist, University of Colorado, USA
<b>Frequency and distribution of LGMDs across the world.</b> <ul style="list-style-type: none"> <li>• Insights from the NGS screening Focus in LATAM</li> <li>• Recently published papers in USA</li> </ul>	<b>Dr. Tahseen Mozaffar</b> , Neurologist, UC Irvine, USA
<b>Diagnostic journey of the LGMD patient.</b> <ul style="list-style-type: none"> <li>• Differential diagnosis – other neuromuscular disorders with limb girdle patterns of weakness (Pompe, adult-onset SMA, etc)</li> </ul>	<b>Dr. Jeff Statland</b> , Neurologist, Kansas University, USA
<b>Most frequent recessive forms of LGMD R1 CAPN3, R2 DYSF, R12 ANOS</b> <ul style="list-style-type: none"> <li>• Including an introduction to Pathophysiology</li> </ul>	<b>Dr. Nick Johnson</b> , Neurologist, Virginia Commonwealth University, USA
<b>Most frequent recessive forms of LGMD R3-6SGCA-G, and R9 FKR1 and dystroglycanopathies</b> <ul style="list-style-type: none"> <li>• Including an introduction to Pathophysiology</li> </ul>	<b>Dr. Kathy Mathews</b> , Neurologist University of Iowa, USA
<b>Dominant LGMD ** or R7, R10?</b> <ul style="list-style-type: none"> <li>• Including an introduction to Pathophysiology</li> </ul>	<b>Dr. C. Chris Wehl</b> , Neurologist, University of Washington – St. Louis, USA
<b>Uses and applications of the muscle biopsy and other molecular methods for diagnosis in LGMD</b>	<b>Dr. Jim Dowling</b> , Neurologist, The Hospital for Sick Children, Canada
<b>Uses and applications of muscle MRI in LGMDs</b>	<b>Professor Jordi Diaz Manera</b> , Neurologist, John Walton Muscular Dystrophy Research Centre, UK
<b>Best practice on genetic diagnostic approaches When to use NGS, WES or WGS?</b>	<b>Dr. Monkol Lek</b> , Assistant Professor, Yale School of Medicine, USA
<b>Clinical trials landscape &amp; emerging therapies</b>	<b>Dr. Kathryn Wagner</b> , Neurologist, Kennedy Krieger Institute, USA

Thursday 24 <sup>th</sup> September	
<b>Natural history of the most frequent LGMDs</b>	<p><b>Dr. Lindsay Alfano</b>, Physical Therapist, Nationwide Children’s Hospital</p> <p><b>Dr. Meredith James</b>, Physiotherapist, John Walton Muscular Dystrophy Research Centre, UK</p>
<b>Best practice for Care management 1. Orthopaedics care</b>	<b>Dr. Linda Lowes</b> , Physical Therapist, Nationwide Children’s Hospital
<b>Best practice for Care management - Cardiological care</b>	<b>Dr. Linda Cripe</b> , Cardiologist, Nationwide Children’s Hospital, USA
<b>Best practice for Care management - Respiratory care</b>	<b>Dr Grace Paul</b> , Paediatric Pulmonologist, Nationwide Children’s Hospital, USA
<b>Registries</b> <ul style="list-style-type: none"> <li>• <b>Why are they needed</b></li> <li>• <b>Practicalities of setting up a registry</b></li> </ul>	<b>Dr Victoria Hodgkinson</b> , National Program Manager, TREAT-NMD SMA Registries, Canada
<b>Workshop 1. Physiotherapy and other clinical care considerations</b> <p><b>Dr. Lindsay Alfano</b>, Physical Therapist, Nationwide Children’s Hospital</p> <p><b>Dr. Linda Lowes</b>, Physical Therapist, Nationwide Children’s Hospital</p> <p><b>Dr. Meredith James</b>, Physiotherapist, John Walton Muscular Dystrophy Research Centre, UK</p> <p><b>Dr. Anna Mayhew</b>, Physiotherapist, John Walton Muscular Dystrophy Research Centre, UK</p> <ul style="list-style-type: none"> <li>• <b>Physiotherapy clinical care considerations</b> <ul style="list-style-type: none"> <li>○ Exercise, stretching, bracing, equipment</li> </ul> </li> <li>• <b>Outcome measures</b> <ul style="list-style-type: none"> <li>○ Strength and functional testing</li> <li>○ Patient reported measures</li> </ul> </li> <li>• <b>Occupational therapy</b></li> <li>• <b>General nutrition</b> <ul style="list-style-type: none"> <li>○ Examining the scientific evidence of some common diets and supplements</li> </ul> </li> </ul>	<b>Workshop 2. Exemplary clinical cases</b> <p><b>Professor Jordi Diaz Manera</b>, Neurologist, John Walton Muscular Dystrophy Research Centre, UK</p> <p><b>Dr. C. Chris Wehl</b>, Neurologist, University of Washington – St. Louis, USA</p> <p><b>Dr. Nick Johnson</b>, Neurologist, Virginia Commonwealth University, USA</p> <p><b>Dr. Jim Dowling</b>, Neurologist, The Hospital for Sick Children, Canada</p> <ul style="list-style-type: none"> <li>• <b>Demonstration and group discussion 3-4 case studies</b></li> </ul>